menu
    • menu
    PHARMACOMPASS
    PHARMACOMPASS

    Grow Your Pharma Business Digitally
    X
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Merck Data at ACC.25 Showcases Advancements in Cardiovascular

    BUSINESSWIRE

    Merck Halts Phase 3 HYPERION Trial For WINREVAIR Early

    BUSINESSWIRE

    Merck wins UK approval for lung disease drug acquired in $11 B deal

    REUTERS

    Merck mystified by sudden `step down` in Gardasil sales in China

    FIERCE PHARMA

    Merck aims to `outnumber` pulmonary arterial hypertension

    FIERCE PHARMA

    Merck`s Biologic Winrevair (sotatercept) Receives Approval in U.S

    FDA

    US FDA approves Merck`s therapy for rare lung condition

    REUTERS

    Merck Presents New Analyses Supporting the Promising Potential of Sotatercept

    BUSINESSWIRE

    Merck unwraps full PIII data on the centerpiece from its $11.5B Acceleron buyout

    ENDPTS

    Merck cardio plan forms as sotatercept, PCSK9 inhibitor impress

    FIERCE BIOTECH

    Merck`s drug boosts exercise capacity in pulmonary hypertension

    BUSINESSWIRE

    Merck to Present New Data for Sotatercept and MK-0616 at ACC.23/WCC

    BUSINESSWIRE

    Is Merck Moving Toward Another Blockbuster Drug Launch?

    FOOL

    Merck nails phase 3 sotatercept win a year after acquiring it

    FIERCEBIOTECH

    Merck`s reported $11B Acceleron buy could face antitrust hurdles

    FIERCEPHARMA

    Merck emerges as lead bidder in potential Acceleron buyout — report

    ENDPTS

    Mystery suitor lines up $11B Acceleron acquisition: report

    FIERCEBIOTECH

    Acceleron Receives Orphan Designation from the (EC) for Sotatercept

    BUSINESSWIRE

    Acceleron Receives Orphan Designation from the (EC) for Sotatercept

    BUSINESSWIRE

    Acceleron Announces Clinical Trial Updates, Preclinical on Sotatercept

    BIOSPACE

    Acceleron to Host Conference Call & Webcast to Review Ph2 Trial of Sotatercept

    BUSINESSWIRE

    Acceleron Announces Publication in Science Translational Medicine Sotatercept

    BUSINESSWIRE

    Acceleron Completes Target Enrollment in the PULSAR Phase 2 Trial of Sotatercept

    BIOSPACE

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.